Annual Cash & Cash Equivalents
$18.26 M
+$13.99 M+327.97%
31 December 2023
Summary:
Galera Therapeutics annual cash & cash equivalents is currently $18.26 million, with the most recent change of +$13.99 million (+327.97%) on 31 December 2023. During the last 3 years, it has risen by +$2.38 million (+15.03%). GRTX annual cash & cash equivalents is now -8.07% below its all-time high of $19.86 million, reached on 31 December 2021.GRTX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$10.75 M
-$2.72 M-20.18%
30 June 2024
Summary:
Galera Therapeutics quarterly cash and cash equivalents is currently $10.75 million, with the most recent change of -$2.72 million (-20.18%) on 30 June 2024. Over the past year, it has dropped by -$13.63 million (-55.91%). GRTX quarterly cash and cash equivalents is now -72.06% below its all-time high of $38.47 million, reached on 30 June 2021.GRTX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GRTX Cash And Cash Equivalents Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +328.0% | -55.9% |
| 3 y3 years | +15.0% | -39.0% |
| 5 y5 years | +23.3% | -31.6% |
GRTX Cash And Cash Equivalents High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -8.1% | +328.0% | -58.1% | +152.0% |
| 5 y | 5 years | -8.1% | +328.0% | -72.1% | +152.0% |
| alltime | all time | -8.1% | +328.0% | -72.1% | +152.0% |
Galera Therapeutics Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| June 2024 | - | $10.75 M(-20.2%) |
| Mar 2024 | - | $13.47 M(-26.2%) |
| Dec 2023 | $18.26 M(+328.0%) | $18.26 M(-25.1%) |
| Sept 2023 | - | $24.38 M(+0.3%) |
| June 2023 | - | $24.30 M(-5.4%) |
| Mar 2023 | - | $25.69 M(+502.1%) |
| Dec 2022 | $4.27 M(-78.5%) | $4.27 M(-66.5%) |
| Sept 2022 | - | $12.73 M(-26.7%) |
| June 2022 | - | $17.38 M(-11.6%) |
| Mar 2022 | - | $19.64 M(-1.1%) |
| Dec 2021 | $19.86 M | $19.86 M(+12.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2021 | - | $17.63 M(-54.2%) |
| June 2021 | - | $38.47 M(+181.0%) |
| Mar 2021 | - | $13.69 M(-13.8%) |
| Dec 2020 | $15.87 M(-13.5%) | $15.87 M(+4.2%) |
| Sept 2020 | - | $15.23 M(-4.1%) |
| June 2020 | - | $15.88 M(-26.4%) |
| Mar 2020 | - | $21.58 M(+17.6%) |
| Dec 2019 | $18.36 M(+23.9%) | $18.36 M(+16.8%) |
| Sept 2019 | - | $15.72 M(-2.9%) |
| June 2019 | - | $16.20 M(+9.3%) |
| Dec 2018 | $14.81 M(+140.1%) | $14.81 M |
| Dec 2017 | $6.17 M | - |
FAQ
- What is Galera Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Galera Therapeutics?
- What is Galera Therapeutics annual cash & cash equivalents year-on-year change?
- What is Galera Therapeutics quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Galera Therapeutics?
- What is Galera Therapeutics quarterly cash and cash equivalents year-on-year change?
What is Galera Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of GRTX is $18.26 M
What is the all time high annual cash & cash equivalents for Galera Therapeutics?
Galera Therapeutics all-time high annual cash & cash equivalents is $19.86 M
What is Galera Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, GRTX annual cash & cash equivalents has changed by +$13.99 M (+327.97%)
What is Galera Therapeutics quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of GRTX is $10.75 M
What is the all time high quarterly cash and cash equivalents for Galera Therapeutics?
Galera Therapeutics all-time high quarterly cash and cash equivalents is $38.47 M
What is Galera Therapeutics quarterly cash and cash equivalents year-on-year change?
Over the past year, GRTX quarterly cash and cash equivalents has changed by -$13.63 M (-55.91%)